Skip to main content
CVS logo

CVS · CVS HEALTH Corp · Documents

Track CVS — free
Market Cap
$109.79B
Shares
1.28B
Volume · Nov 17 13.62M Avg daily vol (3M) 9.11M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $402.07B up 7.8% 10-K filed Feb 10, 2026 Quarterly report FY2026 Q3 Revenue $108.4B up 5.4% 10-Q filed Nov 4, 2026 Latest results Raises 2026 Guidance as Revenue Grows 5.4% 8-K filed Nov 4, 2026 Earnings call Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 4
Earnings call
Split into two publicly traded companies planned for first half of 2028

CVS Health expects its separation into two independent, publicly traded companies to be completed in the first half of 2028, raised 2026 adjusted EPS guidance to at least $8.20 and forecast at least $8.65 for 2027.

4 source passages
Today, we announced our intention to separate into two independent, publicly traded companies. We expect the separation transaction to be tax-free for U.S. federal income tax purposes and to be completed in the first half of 2028, subject to customary conditions, including final board approval, Form 10 effectiveness, and receipt of customary tax confirmation. Building on our continued strong performance so far this year, we are raising our full year 2026 adjusted earnings per share guidance to at least $8.20. Pulling it all together and reflecting the strong performance we saw in the third quarter, we now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Two-company split planned as operating income surges

CVS Health plans to separate into CVS Health and CVS Pharmacy in the first half of 2028; nine-month operating income increased $10.4 billion, or 408.2%, as prior-year charges did not recur.

Revenue $108.4B ▲ 5.4% Net income $2.17B Diluted EPS $1.68
Read from the MD&A section
4 source passages
On November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction that is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. The healthcare solutions company, in the interim, will be referred to as CVS Health. The retail pharmacy and community healthcare company will be named CVS Pharmacy. The separation is expected to be completed in the first half of 2028, subject to customary conditions, including, among others, final approval by the CVS Health Board of Directors, effectiveness of a Form 10 registration statement filed with the SEC and receipt of customary confirmation that the separation is expected to be tax-free to CVS Health and its shareholders. Operating income increased $10.4 billion, or 408.2%, in the nine months ended September 30, 2026 compared to the prior year primarily due to the absence of the $5.7 billion goodwill impairment charge and the $1.2 billion in legacy litigation charges, both recorded in the prior year, as well as improved operating performance across all operating segments. Open the document at this passage
Nov 4
Current report 8-K
Plans separation into two publicly traded healthcare companies

CVS Health intends to separate into a healthcare solutions company and CVS Pharmacy in the first half of 2028; David Joyner and Prem Shah will lead the respective companies as CEOs.

Regulation FD disclosure
4 source passages
CVS Health® (NYSE: CVS) today announced that it intends to separate into two independent, publicly traded companies, each committed to innovating to make healthcare more affordable, accessible, and simpler to navigate for the millions of people each serves. Expected to be completed in the first half of 2028 by means of a separation that is intended to be tax-free to CVS Health and its shareholders The pharmacy company, CVS Pharmacy, will continue to serve as the most frequent healthcare touchpoint for communities across the nation. Upon separation, David Joyner, currently Chairman and CEO of CVS Health, will be the Chairman and CEO of the healthcare solutions company, and Prem Shah, currently Group President of CVS Health, will be the CEO of CVS Pharmacy. Open the document at this passage
Nov 4
Current report 8-K
Raises 2026 Guidance as Revenue Grows 5.4%

CVS Health reported third-quarter revenue of $108.4 billion, up 5.4%, and Adjusted EPS of $2.09, while raising full-year 2026 GAAP EPS guidance to at least $6.98, Adjusted EPS to at least $8.20 and cash flow to at least $15.5 billion.

Financial results
7 source passages
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2026. Third quarter total revenues increased to $108.4 billion, up 5.4% year-over-year Adjusted EPS of $2.09 Raising full-year 2026 guidance: GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04 Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10 Cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $106.1B ▲ 7.3% Net income $2.98B ▲ 191.8% Diluted EPS $2.31 ▲ 188.8%
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $100.43B ▲ 6.2% Net income $2.94B ▲ 65.4% Diluted EPS $2.30 ▲ 63.1%
Apr 3
Proxy statement DEF 14A Meeting May 14, 2026
Proxy statement AI summary on its way
Feb 10
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $402.07B ▲ 7.8% Net income $1.77B ▼ 61.7% Diluted EPS $1.39 ▼ 62.0%
2025
Jul 31
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $98.92B ▲ 8.4% Net income $1.02B ▼ 42.3% Diluted EPS $0.80 ▼ 43.3%
May 1
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $94.59B ▲ 7.0% Net income $1.78B ▲ 59.8% Diluted EPS $1.41 ▲ 60.2%
Feb 12
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $372.81B ▲ 4.2% Net income $4.61B ▼ 44.7% Diluted EPS $3.66 ▼ 43.4%
2024
Showing 1–50 of 205 documents
Key facts CIK 64803 CUSIP 126650100 13F (30d) 1822 filings 1707 filers Visit website Investor relations